levofloxacin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   137 Trials   137 Trials   5343 News 


«12...1920212223242526272829...9091»
  • ||||||||||  levofloxacin / Generic mfg., enoxaparin sodium / Generic mfg.
    New trial:  D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy (clinicaltrials.gov) -  Sep 22, 2023   
    P=N/A,  N=80, Not yet recruiting, 
  • ||||||||||  Fetroja (cefiderocol) / Shionogi
    Journal, Gram negative:  What is the clinical significance of 'heteroresistance' in non-fermenting Gram-negative strains? (Pubmed Central) -  Sep 20, 2023   
    Although in-vitro detection of heteroresistance in non-fermenting GNB has not been associated with in-vivo treatment failure, its presence may suggest to prefer combination regimens instead monotherapy when treating infections by nonfermenters. Further studies are needed to clarify the clinical significance of heteroresistance.
  • ||||||||||  levofloxacin / Generic mfg., rifampicin / Generic mfg., moxifloxacin intravenous / Generic mfg.
    Journal:  Fluoroquinolone resistance mutations among Mycobacterium tuberculosis and their interconnection with treatment outcome. (Pubmed Central) -  Sep 18, 2023   
    The most common hetero-resistance mutation pattern observed in GyrA gene was wild type plus Asp94Gly mutation in 24.6% of isolates. GyrA MUT3C hybridization corresponding to single-point mutation of aspartic acid to glycine at codon 94 constitutes the most common mutation in GyrA gene locus in M. tuberculosis with significant association with treatment outcome as died compared to those with treatment outcome as cured.
  • ||||||||||  ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant (clinicaltrials.gov) -  Sep 18, 2023   
    P2,  N=308, Active, not recruiting, 
    This finding reveals the effect of different exposure sequences of MoS nanoparticles and antibiotic for plant-soil systems. Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2023 --> Apr 2024
  • ||||||||||  FML, FML Forte (fluorometholone ophthalmic suspension) / AbbVie
    Journal:  Lately Diagnosed Acanthamoeba Keratitis Manifesting as an Intrastromal Corneal Abscess: A Case Report. (Pubmed Central) -  Sep 15, 2023   
    After 3 weeks of worsening symptoms, she was diagnosed with bacterial corneal ulcer and treated with levofloxacin eye drops every 2 hr...The patient received polyhexamethylene biguanide 0.02% every 2 hr and oral ketoconazole 200 mg twice a day, which resulted in improvement in her signs and symptoms within 10 days...At the 9-month follow-up visit, the best-corrected visual acuity was 5/10 with a superficial central stromal scar at slitlamp examination. Acanthamoeba infection should be considered in contact lens wearers who present with intrastromal corneal abscess.
  • ||||||||||  levofloxacin / Generic mfg.
    Enrollment open:  Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke (clinicaltrials.gov) -  Sep 15, 2023   
    P=N/A,  N=100, Recruiting, 
    Acanthamoeba infection should be considered in contact lens wearers who present with intrastromal corneal abscess. Not yet recruiting --> Recruiting
  • ||||||||||  Cubicin (daptomycin) / Merck (MSD)
    Near Fatal Anaphylaxis in a Patient with Multiple Drug Intolerance Syndrome (MDIS) (Monitor 02) -  Sep 14, 2023 - Abstract #ACAAI2023ACAAI_733;    
    Due to wound cultures positive for MRSA and Pseudomonas, levofloxacin was changed to meropenem, which she previously tolerated...She required cardiopulmonary resuscitation, including two doses of 1 mg IV epinephrine and intubation prior to return of spontaneous circulation...Her cellulitis was subsequently treated with daptomycin, metronidazole, and aztreonam...Her baseline tryptase > 8 ng/mL raises the possibility of underlying HAT. Further research is necessary to enhance our understanding of carbapenem anaphylaxis.
  • ||||||||||  levofloxacin / Generic mfg.
    Pneumocystis Jirovecii Presenting As Pulmonary Mass In Patient With Common Variable Immunodeficiency And Hematologic Malignancy (Monitor 06) -  Sep 14, 2023 - Abstract #ACAAI2023ACAAI_644;    
    He was prescribed a course of levofloxacin with temporary improvement of symptoms, but shortly thereafter the cough worsened and he began to experience hemoptysis...Chest CT obtained at 4 months showed near complete resolution of mass with linear scarring as we continue to follow this patient closely. Discussion To our knowledge, we present the first reported case of a patient with CVID with concurrent B-cell lymphoma and PJP infection in the setting of normal CD4+ counts.
  • ||||||||||  Invanz (ertapenem) / Merck (MSD)
    Journal:  Patterns of Drug Resistance and Bacterial Pathogen Distribution in Patients with Urinary Tract Infections in the Jiaxing Region from 2020 to 2022. (Pubmed Central) -  Sep 13, 2023   
    As far as antibiotic resistance was concerned, Escherichia coli had a greater than 50% resistance rate to ampicillin (76.1%), ciprofloxacin (58.6%), and levofloxacin (51.2%)...Low levels of resistance were seen to ertapenem (0.1%), imipenem (0.7%), meropenem (0.7%), piperacillin/tazobactam (0.7%), and nitrofurantoin (1.8%)...The resistance rates to nitrofurantoin, ceftriaxone, and ciprofloxacin were 37.4%, 37.1%, and 35.1%, respectively...Two species of enterococci were highly sensitive to tigecycline and linezolid (100%), and a small number of norvancomycin-resistant strains (0.2%/two strains) were found...The isolated pathogens showed different sensitivity patterns. Antibiotics should be selected reasonably according to the sensitivity mode of pathogenic bacteria to effectively treat and prevent urinary tract infections.
  • ||||||||||  levofloxacin / Generic mfg., fosfomycin tromethamine / Generic mfg.
    Journal:  Daily fosfomycin versus levofloxacin for complicated urinary tract infections. (Pubmed Central) -  Sep 12, 2023   
    P4
    Fosfomycin is a drug that is routinely used for the treatment of uncomplicated cystitis. This study shows that fosfomycin could be an oral alternative as step-down therapy for the treatment of complicated urinary tract infections, with a clinical cure rate comparable to levofloxacin but a lower microbiological success rate 3 weeks from start of antibiotics.
  • ||||||||||  levofloxacin / Generic mfg., acarbose / Generic mfg.
    Journal:  Exploring Kinnow mandarin's hidden potential: Nature's key to antimicrobial and antidiabetic gold nanoparticles (K-AuNPs). (Pubmed Central) -  Sep 11, 2023   
    Furthermore, the anti-diabetic efficacy was evaluated through ?-amylase and ?-glucosidase experiments, comparing K-AuNPs to pure KAPE and the standard inhibitor acarbose...To sum up, the process of producing K-AuNPs utilizing Kinnow mandarin peel extracts demonstrates a powerful antibacterial and antidiabetic remedy sourced from previously discarded materials. These findings signify a significant leap forward in the domain of natural product exploration, with the potential to fundamentally reshape modern healthcare approaches.
  • ||||||||||  levofloxacin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg., minocycline / Generic mfg.
    Journal:  The Relationship between the Biofilm Genes and Antibiotic Resistance in Stenotrophomonas maltophilia. (Pubmed Central) -  Sep 11, 2023   
    Moreover, smf-1, rmlA, and spgM genes were presented in all strong biofilm producers. Although the overall resistance rate to the evaluated antibiotics was high, there was no statistically significant relation between antibiotic resistance and the type of biofilm.
  • ||||||||||  Takecab (vonoprazan) / Takeda, Phathom Pharma
    Review, Journal:  Update on the second-line treatment of Helicobacter pylori infection: a narrative review. (Pubmed Central) -  Sep 8, 2023   
    In conclusion, the eradication rate of levofloxacin-amoxicillin triple therapy is suboptimal in the second-line treatment of H. pylori infection now. Currently, a standard bismuth quadruple therapy (tetracycline-metronidazole quadruple therapy), a tetracycline-levofloxacin quadruple therapy, an amoxicillin-levofloxacin quadruple therapy, a levofloxacin-based sequential quadruple therapy or a high-dose PPI-amoxicillin dual therapy is recommended for the second-line treatment of H. pylori infection.